Completion of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations enables public reimbursement of Vanflyta across Canada, with Quebec reimbursing Vanflyta in May 2026 Reimbursement includes use ...

TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

Data at SOHO 2026 show how FLT3 inhibitors and venetoclax-based triplets have reshaped induction, consolidation, and maintenance therapy in FLT3-mutated AML. At the 2026 Society of Hematologic ...

Company?s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD. A pronounced survival benefit occurred with maintenance ...

Impact of FLT3 inhibitors on the outcomes of FLT3-ITD-positive acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis. This is an ASCO ...

The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...

TORONTO, May 28, 2026 /CNW/ - Vanflyta® (quizartinib) is now publicly reimbursed in Canada in Quebec, enabling access for adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia ...